Monocyclic L-Nucleosides, analogs and uses thereof

• US 6,130,326 A
• Filed: 04/14/1999
• Issued: 10/10/2000
• Est. Priority Date: 10/16/1996
• Status: Expired due to Fees

• Current Assignee: Ribapharm Inc. (Bausch Health Cos., Inc.)
• Original Assignee: ICN Pharmaceuticals, Inc (Bausch Health Cos., Inc.)
• Inventors: Tam, Robert, Averett, Devron, Ramasamy, Kandasamy
• Primary Examiner(s): Geist, Gary
• Assistant Examiner(s): CRANE, LAWRENCE E
• Application Number:
  US09/291,903
• Time in Patent Office: 545 Days
• Field of Search: 514/43, 514/46, 514/49, 514/50, 536/28.1, 536/28.2, 536/28.3, 536/28.4, 536/28.5, 536/28.53, 536/28.6, 536/28.7, 536/28.8, 544/224, 548/255, 548/252.2, 548/300.1, 548/356.1, 548/400
• US Class Current: 536/28.7
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07H 19/04 Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Abstract

Novel monocyclic L-Nucleoside compounds have the general formula ##STR1## Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

Claims

1. The compound consisting essentially of L-ribavirin. OH.

2. A compound of claim 1 wherein the compound consisting essentially of an α

-nucleoside.

3. A compound of claim 2 wherein the compound consisting essentially of β

-nucleoside.

4. A pharmaceutical comprising a compound according to claim 1, or a pharmaceutically acceptable ester or salt thereof, admixed with at least one pharmaceutically acceptable carrier.